# CIPLA (CIPLA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/cipla

## Current market snapshot

- Exchange: BSE
- Country: India
- Price: ₹1,329.6
- Change: +1.40%
- As of: 2026-10-13
- 1D return: +1.40%
- 5D return: -0.79%
- 1M return: -2.66%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-10-13_

### Technical Outlook

As of October 13, 2026, Cipla's technical setup indicates a bearish trend across daily and monthly timeframes, with the price trading below key moving averages and the Supertrend indicator. The weekly timeframe shows a conflicting signal, with the price above the Supertrend but still below major moving averages. Daily trend conviction is developing with an ADX of 23.83, while monthly and weekly ADX values of 18.2 and 18.23, respectively, suggest weak trend strength. The stock is positioned in the lower-middle part of its 20-day and 252-day ranges, at +29.1% and +32.3% respectively, and near the lower end of its 50-day range at +19.2%. Recent market activity includes one positive attention event, one downside event, and one neutral event in the last 30 days.

Risk is characterized by an annualized volatility of +20.9% and a current drawdown of -20.1%. The nearest support is observed at ₹1326.83 (0.21% below the current price), followed by ₹1319.07 (0.79% below). Resistance is noted at ₹1336.27 (0.50% above) and ₹1344.39 (1.11% above). The current bearish setup would be confirmed by a sustained move below the support at ₹1319.07, while a break above resistance at ₹1336.27 could signal a potential shift in momentum.

- Bearish trend on daily and monthly charts, with mixed signals on the weekly timeframe.
- Stock is positioned in the lower-middle part of its 20-day and 252-day trading ranges.
- Annualized volatility stands at +20.9% with a current drawdown of -20.1%.
- Nearest support is at ₹1326.83 (-0.21%) and resistance is at ₹1336.27 (+0.50%).
- Confirmation of the bearish setup requires a move below ₹1319.07; a break above ₹1336.27 could indicate a shift.

- Inside Bar
- Hammer
- Doji
- Bearish Engulfing Reversal

### News Context

Cipla Limited has announced its board meeting scheduled for October 27, 2026, to review the unaudited financial results for the half-year ended September 2026. In preparation for this announcement, the company has implemented a trading window closure from October 1, 2026, to October 29, 2026. Earlier in the reporting period, on September 24, 2026, Cipla's Operations and Administrative Committee approved the allotment of 12,168 fully paid-up equity shares under its Employee Stock Option Schemes. This allotment resulted in an increase of the company's issued, subscribed, and paid-up share capital to ₹1,61,57,41,230, comprising 80,78,70,615 equity shares.

- Cipla's board will convene on October 27, 2026, to consider unaudited financial results for the half-year ending September 2026.
- The company's trading window is closed from October 1, 2026, to October 29, 2026, for financial results declaration.
- On September 24, 2026, 12,168 equity shares were allotted under ESOPs.
- The share allotment on September 24, 2026, increased the total paid-up capital to ₹1,61,57,41,230.
- The total number of equity shares outstanding following the allotment is 80,78,70,615.

- Financial Results |Meeting Date: 27-Oct-2026
- CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation
- Board Meeting Intimation |Meeting Date: 27-Oct-2026
- Cipla Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL
- Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares. |SUBJECT: ESOP/ESOS/ESPS

### Official Filings

Cipla Limited has announced a board meeting scheduled for October 27, 2026, to consider the unaudited financial results for the half-year ended September 2026. In preparation for this, the company has closed its trading window from October 1, 2026, to October 29, 2026. The company also disclosed the allotment of 12,168 fully paid-up equity shares on September 24, 2026, under its employee stock option schemes (ESOS 2013-A and Cipla ESAR Scheme 2021). This allotment increased the company's issued and paid-up share capital to ₹1,61,57,41,230, comprising 80,78,70,615 equity shares. Additionally, Cipla is proceeding with the amalgamation of its wholly-owned subsidiary, Inzpera Healthsciences Limited, following a National Company Law Tribunal (NCLT) order dated August 18, 2026. While the NCLT dispensed with shareholder and creditor meetings for Cipla, shareholders and unsecured creditors have a 30-day period from receiving notice to raise objections.

- Board meeting scheduled for October 27, 2026, to approve unaudited financial results for the half-year ended September 2026.
- Trading window closed from October 1, 2026, to October 29, 2026, for financial results declaration.
- On September 24, 2026, 12,168 equity shares were allotted under employee stock option schemes, increasing paid-up capital to ₹1,61,57,41,230.
- Amalgamation of Inzpera Healthsciences Limited with Cipla Limited is proceeding, with a 30-day window for shareholder/creditor objections post-notice.

- [Financial Results |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/CIPLA_28092026185535_Pre_Board_Meeting_SE_intimation_-_Oct_2026_signed.pdf)
- [CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Board Meeting Intimation |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Cipla Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_792_WebXMLFile_20260928_192723248.xml)
- [Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/CIPLA_24092026190246_SE_Intimationsigned.pdf)
- [CIPLA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_792_WebXMLFile_20260924_190436538.xml)
- [Cipla Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_792_WebXMLFile_20260923_150618335.xml)
- [Cipla Limited has informed the Exchange about change in Senior Management Personnel. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/CIPLA_22092026225713_Cipla_SE_SMP_Change_20260921_signed.pdf)
- [Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_18092026173202_Niche99ESGRating18092026Signed.pdf)
- [Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company. |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf)

### Fundamentals

Cipla's recent financial performance shows a sequential increase in revenue, operating profit, and net profit for the quarter ending in September 2026 (Q1 FY27) compared to the prior quarter (Q4 FY26). Revenue from operations rose to ₹7,119.28 crore from ₹6,541.20 crore, while net profit increased to ₹785.55 crore from ₹542.51 crore. This indicates an improvement in profitability on a sequential basis. However, looking at longer-term trends, the Compounded Sales Growth over 3 years was 7% and over 5 years was 8%, while Compounded Profit Growth over the same periods was 10%. The TTM Compounded Profit Growth stands at -34%, suggesting recent profit declines. Return on Equity has been around 12-15% over the last few years. The company's balance sheet shows increasing investments and fixed assets, with CWIP (Capital Work-in-Progress) also rising, indicating ongoing capital expenditure. Borrowings have fluctuated, decreasing from ₹559 crore in March 2024 to ₹438 crore in March 2025, but projected to increase to ₹614 crore by March 2026. Free Cash Flow has shown variability, decreasing significantly in the projected March 2026 period to ₹928 crore from ₹3,490 crore in March 2025. The Cash Conversion Cycle has been lengthening, moving from 182 days in March 2024 to a projected 202 days by March 2026, driven by increasing inventory days. Shareholding patterns show a decrease in promoter holdings from 33.46% in September 2023 to a projected 29.22% in September 2025, while DII holdings are projected to increase significantly. The most important checkpoint for the next results will be the sustainability of sequential profit growth and the trend in cash flow generation.

- Sequential increase in Revenue from Operations to ₹7,119.28 crore and Net Profit to ₹785.55 crore for Q1 FY27.
- Profitability shows a positive sequential trend, but TTM Compounded Profit Growth is -34%.
- Investments and fixed assets are increasing, with projected higher borrowings by March 2026.
- Monitor the sustainability of sequential profit growth and the trend in cash flow generation.

### Bull Case

The company's weekly trend analysis indicates a bullish supertrend direction, suggesting a potentially positive short-term market setup. However, daily and monthly trend analyses both show a bearish supertrend direction, alongside negative slopes for moving averages, indicating prevailing caution across longer timeframes. The stock is trading at ₹1329.6 as of October 13, 2026, with a market capitalization of ₹1,059,344,781,551.1. Nearest resistance is observed at ₹1336.27, representing a 0.50% increase from the current price, while immediate support is noted at ₹1326.83, a 0.21% decrease.

- Weekly trend shows a bullish supertrend direction.
- Current stock price as of October 13, 2026, is ₹1329.6.
- Nearest resistance level is ₹1336.27 (0.50% above current price).
- Nearest support level is ₹1326.83 (0.21% below current price).

- [Financial Results |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/CIPLA_28092026185535_Pre_Board_Meeting_SE_intimation_-_Oct_2026_signed.pdf)
- [CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Board Meeting Intimation |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Cipla Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_792_WebXMLFile_20260928_192723248.xml)
- [Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/CIPLA_24092026190246_SE_Intimationsigned.pdf)
- [CIPLA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_792_WebXMLFile_20260924_190436538.xml)
- [Cipla Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_792_WebXMLFile_20260923_150618335.xml)
- [Cipla Limited has informed the Exchange about change in Senior Management Personnel. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/CIPLA_22092026225713_Cipla_SE_SMP_Change_20260921_signed.pdf)
- [Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_18092026173202_Niche99ESGRating18092026Signed.pdf)
- [Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company. |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf)

### Bear Case

Cipla's technical indicators suggest a cautious outlook. The daily and monthly Supertrend indicators are both in a bearish direction, indicating a prevailing downward trend. The daily chart shows a negative Exponential Moving Average (EMA) 20 slope of -23.12 and a Simple Moving Average (SMA) 20 slope of -15.28, further reinforcing this bearish sentiment. The company has experienced a year-to-date return of -11.4% and a 1-year return of -15.0%. Current market conditions show the stock trading near support levels, with the nearest support at ₹1326.83, which is 0.21% below the current price of ₹1329.6. Resistance is observed at ₹1336.27, a mere 0.50% above the current price.

- Daily and monthly Supertrend indicators are bearish.
- Year-to-date return is -11.4% and 1-year return is -15.0%.
- Nearest support level is ₹1326.83 (0.21% below current price).
- Nearest resistance level is ₹1336.27 (0.50% above current price).

- [Financial Results |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/CIPLA_28092026185535_Pre_Board_Meeting_SE_intimation_-_Oct_2026_signed.pdf)
- [CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Board Meeting Intimation |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Cipla Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_792_WebXMLFile_20260928_192723248.xml)
- [Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/CIPLA_24092026190246_SE_Intimationsigned.pdf)
- [CIPLA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_792_WebXMLFile_20260924_190436538.xml)
- [Cipla Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_792_WebXMLFile_20260923_150618335.xml)
- [Cipla Limited has informed the Exchange about change in Senior Management Personnel. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/CIPLA_22092026225713_Cipla_SE_SMP_Change_20260921_signed.pdf)
- [Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_18092026173202_Niche99ESGRating18092026Signed.pdf)
- [Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company. |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf)

### FAQs

**When will Cipla announce its financial results for the half-year ended September 2026, and what is the trading window status?**

Cipla Limited's board is scheduled to meet on October 27, 2026, to consider the unaudited financial results for the half-year ended September 2026. The company has closed its trading window from October 1, 2026, to October 29, 2026, for this purpose.

**What recent share allotment has occurred at Cipla?**

On September 24, 2026, Cipla Ltd. allotted 12,168 fully paid-up equity shares of ₹2 each under its ESOS 2013-A and Cipla ESAR Scheme 2021. This allotment increased the company's issued, subscribed, and paid-up share capital to ₹1,61,57,41,230, representing 80,78,70,615 equity shares.

**What are Cipla's recent performance returns?**

As of October 13, 2026, Cipla's recent returns include +1.4% for the last day, -2.7% for the last month, -6.8% for the last three months, and -15.0% for the last year. Year-to-date, the return is -11.4%.

**What are the nearest support and resistance levels for Cipla's stock?**

The nearest support level for Cipla is at ₹1326.83, which is 0.21% below the current price. The nearest resistance level is at ₹1336.27, which is 0.50% above the current price.

**What is the current technical trend direction for Cipla?**

Based on technical indicators, Cipla's daily trend is currently bearish, while its weekly trend is bullish. The monthly trend is also indicated as bearish.

- [Financial Results |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/CIPLA_28092026185535_Pre_Board_Meeting_SE_intimation_-_Oct_2026_signed.pdf)
- [CIPLA LIMITED has informed the Exchange about Board Meeting to be held on 27-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Board Meeting Intimation |Meeting Date: 27-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- [Cipla Limited has informed the Exchange about Closure of Trading Window |SUBJECT: Trading Window-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_792_WebXMLFile_20260928_192723248.xml)
- [Cipla Limited has informed the Exchange regarding Allotment of 12168 Shares. |SUBJECT: ESOP/ESOS/ESPS](https://nsearchives.nseindia.com/corporate/CIPLA_24092026190246_SE_Intimationsigned.pdf)
- [CIPLA LIMITED has informed the Exchange regarding Allotment of Securities |SUBJECT: Alteration Of Capital and Fund Raising-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_792_WebXMLFile_20260924_190436538.xml)
- [Cipla Limited has informed the Exchange about Change in Directors/KMP/SMP/Auditor/RTA |SUBJECT: Change in Directors/KMP/SMP/Auditor/RTA](https://nsearchives.nseindia.com/corporate/xbrl/CIM_792_WebXMLFile_20260923_150618335.xml)
- [Cipla Limited has informed the Exchange about change in Senior Management Personnel. |SUBJECT: Change in Management](https://nsearchives.nseindia.com/corporate/CIPLA_22092026225713_Cipla_SE_SMP_Change_20260921_signed.pdf)
- [Intimation under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_18092026173202_Niche99ESGRating18092026Signed.pdf)
- [Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company. |SUBJECT: General Updates](https://nsearchives.nseindia.com/corporate/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf)
## Technical analytics

- As of: 2026-10-13
- Daily trend: Moderate Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹1,309.63
- Risk regime: Price Risk Requires Attention

### Support levels
- 1317.1
- 1287.1875
- 1222

### Resistance levels
- 1344.3874999999998
- 1533.2303527832032
- 1574.49375

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +1.40% |
| return_10 | -3.91% |
| return_1m | -2.66% |
| return_1y | -14.97% |
| return_20 | -2.66% |
| return_3m | -6.81% |
| return_5 | -0.79% |
| return_6m | +9.78% |
| return_since_start | -13.05% |
| return_ytd | -11.41% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | elevated_risk |
| label | Price risk requires attention |
| summary | Recent drawdown or price variability is high enough to warrant closer monitoring. |
| maximum_drawdown | -28.32% |
| annualized_volatility | +20.90% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Profit before tax slides 39% year-on-year despite modest revenue growth

Cipla reported a 2.3% increase in revenue from operations to ₹7,119 crore for the quarter ended 30 June 2026. However, profit before tax declined 38.9% to ₹1,082 crore as expenses rose faster than sales. Net profit fell 39.2% and earnings per share dropped to ₹9.77 from ₹16.07 a year ago.

## Revenue

Revenue from operations was ₹7,119 crore in Q1 FY2026-27, compared with ₹6,957 crore in the same quarter last year – a 2.3% increase. Sequentially, revenue recovered by 8.8% from the March 2026 quarter (₹6,541 crore). Other income was ₹210.9 crore for the quarter.

## Profitability and expenses

Profit before tax stood at ₹1,082 crore, down sharply from ₹1,770 crore in Q1 FY2025-26. The effective tax rate remained roughly stable at about 27%, leading to a tax charge of ₹295 crore (previous year: ₹478 crore). Profit for the period totalled ₹785.55 crore, a decline of 39.2% from ₹1,291.61 crore. Basic earnings per share fell to ₹9.77 from ₹16.07.

The drop in profit against only modest revenue growth was driven by costs that increased at a faster pace. Several large expense lines contributed to the cost base in the quarter:

- Cost of materials consumed: ₹1,357 crore  
- Employee benefit expense: ₹1,497 crore  
- Depreciation and amortisation: ₹304 crore  
- Other expenses: ₹1,762 crore, up 3.9% from ₹1,696 crore in the prior-year quarter  
- Finance costs: ₹17 crore, up from ₹14 crore  

While year-on-year comparisons for cost of materials, employee benefits, and depreciation are not available in the supplied figures, other expenses grew at nearly double the pace of revenue, and finance costs also increased. The combination of still-high absolute cost levels and only a small revenue gain compressed profit before tax by 38.9%.

## Management Commentary

Achin Gupta, MD and Global CEO of Cipla, stated: "We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of INR 7,119 Cr. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of $ 162 Mn during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front."

## Key Takeaway

Cipla’s first quarter shows a clear gap between steady, low-single-digit revenue growth and a severe profitability squeeze. Revenue edged up 2.3%, but rising costs – especially the 3.9% rise in other expenses and higher finance costs – pushed profit before tax down by nearly 39% year-on-year. Earnings per share fell from ₹16.07 to ₹9.77. While revenue improved sequentially from the March 2026 quarter, the year-on-year profit decline remains the dominant feature of these results.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +29.21%
- FII holding: +20.20%
- DII holding: +34.35%
- Mutual fund holding: +20.56%
- Retail holding: +6.85%
- Promoter pledged: +0.00%

### Major reported shareholders

- Yusuf Khwaja Hamied — +18.69%
- LICI ULIP-GROWTH FUND — +9.75%
- SOPHIE AHMED — +5.71%
- HDFC TRUSTEE COMPANY LIMITED-HDFC FLEXI CAP FUND — +4.48%
- M K HAMIED — +3.46%
- SBI NIFTY 50 EQUAL WEIGHT INDEX FUND — +3.24%
- ICICI PRUDENTIAL EQUITY SAVINGS FUND — +2.36%
- NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ARB — +1.96%
- DSP NIFTY 50 INDEX FUND — +1.90%
- PARAG PARIKH ARBITRAGE FUND — +1.87%

## Official filings

- 2026-09-28 — Board Meeting Notice: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_28092026185535_Pre_Board_Meeting_SE_intimation_-_Oct_2026_signed.pdf)
- 2026-09-28 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- 2026-09-28 — Board Meeting Notice: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_792_WebXMLFile_20260928_192030118.xml)
- 2026-09-28 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_792_WebXMLFile_20260928_192723248.xml)
- 2026-09-24 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_24092026190246_SE_Intimationsigned.pdf)
- 2026-09-24 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_792_WebXMLFile_20260924_190436538.xml)
- 2026-09-23 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_792_WebXMLFile_20260923_150618335.xml)
- 2026-09-22 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_22092026225713_Cipla_SE_SMP_Change_20260921_signed.pdf)
- 2026-09-18 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_18092026173202_Niche99ESGRating18092026Signed.pdf)
- 2026-09-03 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_03092026164718_Final_SEINT_V2f_signed.pdf)
- 2026-09-03 — Press Release: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_03092026201249_Press_Release_final_signed_f.pdf)
- 2026-09-02 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_02092026195911_Newspaper_Advertisement_final_signed.pdf)
- 2026-08-31 — Press Release: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_31082026155324_Press_release_Covering_SBP_signed.pdf)
- 2026-08-28 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_792_WebXMLFile_20260828_175426180.xml)
- 2026-08-28 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_28082026210952_SE_Intimation_USFDA_VAI.pdf)
- 2026-08-27 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SAIIM_792_WebXMLFile_20260827_153933039.xml)
- 2026-08-27 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_27082026201905_SEIntimation_Aspergen_27082026_Restructuring_Signed.pdf)
- 2026-08-26 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/ALTERATION_OF_CAPITAL_AND_FUND_RAISING_792_WebXMLFile_20260826_174410354.xml)
- 2026-08-26 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_26082026173443_SE_Intimationsigned.pdf)
- 2026-08-25 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_25082026161031_USFDA_inspection_-_Pithampur_25082026_Signed.pdf)
- 2026-08-21 — Shareholding Disclosure: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/SHP_1712107_11082026072853_WEB.xml)
- 2026-08-19 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_19082026170119_NCLTorderintimationsigned.pdf)
- 2026-08-11 — Generic Announcement: Cipla Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_11082026131928_SESNSEESGRating11082026.pdf)
- 2026-08-04 — Generic Announcement: Cipla Limited announced on August 4, 2026, that its wholly-owned subsidiary, InvaGen Pharmaceuticals, Inc., has received the Establishment Inspection Report (EIR) from the USFDA for its Hauppauge, New York manufacturing facility. This report indicates the closure of the Pre-Approval Inspection (PAI) previously conducted by the USFDA. — [Official attachment](https://nsearchives.nseindia.com/corporate/CIPLA_04082026085728_SE_Intimation-US_FDA_EIR04082026.pdf)
- 2026-07-31 — Official Filing: On July 31, 2026, Cipla Limited's Operations and Administrative Committee allotted 7,850 fully paid-up equity shares of INR 2 each. This allotment was pursuant to the exercise of employee stock options and stock appreciation rights under the ESOS 2013-A and Cipla ESAR Scheme 2021. The total number of shares increased by 7,850, and the paid-up share capital increased by INR 15,700.

## News and market events

- 2026-10-05 — BUSINESSTODAY: **Holding pharma stocks? Minor correction offers buying opportunity, says analyst** — pharma stocks, Indian pharma sector, Kranti Batini, Edelweiss Securities, pharma rally, healthcare stocks, hospital stocks, buy pharma on dips, term investment, long term investment, Cipla news, Sun Pharma update, Piramal Pharma news, Aurobindo Pharma news, Indian stock market sectors, defensive sectors India, pharma market outlook, healthcare sector outlook, stock market correction, sectoral investment strategy — [Source](https://www.businesstoday.in/markets/stocks/story/holding-pharma-stocks-minor-correction-is-a-buying-opportunity-says-bathini-559556-2026-10-05)
- 2026-10-05 — The Hindu: **Markets break 8-week losing streak as Financials lead, healthcare & IT drag** — Markets snap eight-week fall as Nifty, Sensex rise; financials lead gains while healthcare and IT drag amid RBI visit, global cues. — [Source](https://www.thehindubusinessline.com/markets/markets-snap-eight-week-losing-streak-financials-lead-healthcare-and-it-drag/article71545803.ece)
- 2026-09-30 — CNBC-TV18: **Market Close Explained: Why Nifty ended lower despite gains in banking stocks** — The Nifty Bank was the relative outperformer, rising 373 points to 54,633, while the Nifty Midcap index gained 13 points to 59,332. — [Source](https://www.cnbctv18.com/market/market-close-explained-why-nifty-ended-lower-despite-gains-in-banking-stocks-20002098.htm)
- 2026-09-29 — MONEYCONTROL: **Pharma stocks gain on US tariff exemption on some specialty drugs** — pharma stocks — [Source](https://www.moneycontrol.com/news/business/markets/pharma-stocks-gain-on-us-tariff-exemption-on-some-specialty-drugs-14040978.html)
- 2026-09-29 — BUSINESSTODAY: **Pharma stocks: Sun Pharma, Dr Reddy’s, Cipla, Biocon and others in focus today; here's why** — Pharma stocks, Sun Pharma, Dr Reddy’s, Cipla, Biocon — [Source](https://www.businesstoday.in/markets/trending-stocks/story/pharma-stocks-sun-pharma-dr-reddys-cipla-biocon-others-in-focus-today-heres-why-558401-2026-09-29)
- 2026-09-27 — BUSINESSTODAY: **India's former top negotiator at WTO. Now he warns of risks in a full-fledged FTA with US** — India US free trade agreement, JS Deepak trade warning, India agriculture trade risks, India US FTA agriculture impact, Indian farmers and US trade, India pharmaceutical industry US trade, India dairy poultry trade, India trade negotiations US, India trade policy agriculture, India US tariff concerns — [Source](https://www.businesstoday.in/latest/economy/story/indias-former-top-negotiator-at-wto-now-he-warns-of-risks-in-a-full-fledged-fta-with-us-558102-2026-09-27)
- 2026-09-22 — REDIFF.COM: **Top Pharma Firms Maintain Volume Growth Amid Market Shift to Chronic Therapies** — India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies. — [Source](https://www.rediff.com/business/report/indias-top-10-pharma-companies-sustain-volume-growth-outperforming-smaller-rivals/20260922.htm)
- 2026-09-22 — NEWS.WEBINDIA123.COM: **Sensex, Nifty open in green on easing crude, softer US bond yields** — The Indian equity markets opened on a positive note on Tuesday supported by easing crude oil prices and softer US bond yields. — [Source](https://news.webindia123.com/news/articles/business/20260922/4501773.html)
- 2026-09-10 — Mint: **Govt plans central licensing for all sterile drugs after quality lapses | Today News** — The move is significant for India’s generic injectable industry, where manufacturing lapses can pose a more immediate risk to patients than defects in medicines taken orally. — [Source](https://www.livemint.com/news/govt-plans-central-licensing-for-all-sterile-drugs-after-240-injection-samples-fail-quality-tests-medicine-11789033517269.html)
- 2026-09-09 — Economic Times: **Why DSP Mutual Fund's Chirag Dagli is betting on CDMO, hospitals and smallcap healthcare stocks** — At the same time, the fund is evaluating hospital expansion, hybrid diagnostics businesses and valuations to identify healthcare companies capable of sustaining growth. — [Source](https://economictimes.indiatimes.com/markets/expert-view/why-dsp-mutual-funds-chirag-dagli-is-betting-on-cdmo-hospitals-and-smallcap-healthcare-stocks/articleshow/133951047.cms)
- 2026-09-07 — The Hindu: **Patient safety in a time of fakes, misbrands and recalls** — Explore the urgent concerns surrounding patient safety amidst rising counterfeit drugs, recalls, and regulatory challenges in healthcare. — [Source](https://www.thehindubusinessline.com/specials/pulse/patient-safety-in-a-time-of-fakes-misbrands-and-recalls/article71436469.ece)
- 2026-09-04 — MONEYCONTROL: **Cipla shares slip after Keytruda biosimilar deal with Qilu, as competition worries weigh; Morgan Stanley cautious** — cipla share price today, cipla stock update, cipla share price target, cipla stock rating, cipla stock outlook, cipla analyst review, cipla qilu deal — [Source](https://www.moneycontrol.com/news/business/markets/cipla-shares-slip-after-keytruda-biosimilar-deal-with-qilu-as-morgan-stanley-stays-cautious-check-target-price-14022457.html)
- 2026-09-04 — The Hindu: **Cipla slips after Qilu Pembrolizumab deal; Morgan Stanley flags crowded field** — Cipla stock trades at ₹1,388, down 0.48% or ₹6.70 from its previous close of ₹1,394.70 — [Source](https://www.thehindubusinessline.com/markets/stock-markets/cipla-slips-after-qilu-pembrolizumab-deal-morgan-stanley-flags-crowded-field/article71427091.ece)
- 2026-09-04 — The Hindu: **Stocks in focus: IEX, PowerGrid, RVNL, APSEZ, Bharat Forge, HEG, brokerage stocks,Cipla among dozen stocks will be in focus** — IEX logs record August volumes; HEG renamed as scheme takes effect — [Source](https://www.thehindubusinessline.com/markets/stocks-in-focus-iex-powergrid-rvnl-apsez-bharat-forge-heg-brokerage-stockscipla-among-dozen-stocks-will-be-in-focus/article71426821.ece)
- 2026-09-04 — The Hindu: **Sensex today | Stock Market Live: Stock to buy today: Kirloskar Oil Engines (₹2,267.40)** — Sensex, Nifty, Share Prices LIVE: The stock of Kirloskar Oil Engines, which has been in a long-term uptrend, witnessed a price correction recently — [Source](https://www.thehindubusinessline.com/markets/sensex-nifty50-today-stock-market-live-updates-4th-september-2026/article71425360.ece)
- 2026-09-02 — MONEYCONTROL: **Trade Spotlight: How should you trade ONGC, Infosys, Alembic Pharma, HCL Technologies, Caplin Point Labs, and others on September 2?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Oil and Natural Gas Corporation,Infosys,Cipla,Alembic Pharmaceuticals,HCL Technologies,Caplin Point Laboratories, — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-ongc-infosys-alembic-pharma-hcl-technologies-caplin-point-labs-and-others-on-september-2-14020366.html)
- 2026-09-01 — CNBC-TV18: **Sun Pharma, Cipla have more upside; Chinese drug deals may lower oncology costs: Systematix** — Vishal Manchanda, Pharma Analyst at Systematix Group, expects more Indian drugmakers to partner with Chinese pharma companies, with their focus on scale and volumes potentially bringing down oncology drug prices. Manchanda also sees smaller CDMO companies offering stronger upside as new contracts and opportunities emerge. — [Source](https://www.cnbctv18.com/market/stocks/sun-pharma-cipla-upside-chinese-drug-deals-oncology-costs-19981425.htm)
- 2026-09-01 — BUSINESS: **Cipla inks exclusive licensing agreement with SBP Group for ADC Rolditamig Deuderuxtecan** — Cipla said that it has entered into an exclusive license and supply agreement with Chia Tai Tianqing Pharmaceutical Group Co. for Rolditamig Deuderuxtecan, a potential best-in-class HER2 bispecific antibody-drug conjugate (ADC). — [Source](https://www.business-standard.com/markets/capital-market-news/cipla-inks-exclusive-licensing-agreement-with-sbp-group-for-adc-rolditamig-deuderuxtecan-126090100190_1.html)
- 2026-09-01 — BUSINESSTODAY: **Top stocks in news: Symbiotech, EPL, Milky Mist, TBZ, Skyways, PVR Inox, Hy-Tech, Cipla, Kotak Bank** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Symbiotec Pharmalab, EPL, Milky Mist Dairy Foods, TBZ, Skyways Air Services, PVR Inox, Hy-Tech Engineers, Cipla, Kotak Mahindra Bank, LEAP India, Tribhovandas Bhimji Zaveri, Happiest Minds Technologies, Brigade Enterprises, NLC India, NCC, Lodha Developers, E2E Networks — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-symbiotech-epl-milky-mist-tbz-skyways-pvr-inox-hy-tech-cipla-kotak-bank-552424-2026-09-01)
- 2026-08-31 — CNBC-TV18: **Stocks to Watch for September 1: ITC, Happiest Minds, HDFC Bank, ONGC and more** — From Oil and Natural Gas Corporation (ONGC) planning to spend more than ₹30,000 crore on capital expenditure this year to Cipla securing exclusive rights to develop and commercialise an experimental HER2-targeted cancer drug in India, South Africa and five other emerging markets, these are the stocks to track ahead of Tuesday's trading session. — [Source](https://www.cnbctv18.com/photos/market/stocks-to-watch-for-september-1-itc-happiest-minds-hdfc-bank-ongc-and-more-19980733.htm)
- 2026-08-31 — Economic Times: **Aurobindo Pharma launches generic Advair Diskus for asthma and COPD in US** — Lannett Company, part of Aurobindo Pharma, has launched generic Advair Diskus in the US, making it the first complex inhalation product from Aurobindo to be marketed there. This market is worth approximately $908 million. Moreover, Cipla's US branch has also obtained FDA approval for the same product, setting the stage for an exciting competition in respiratory treatments. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/aurobindo-pharma-launches-generic-advair-diskus-for-asthma-and-copd-in-us/articleshow/133653548.cms)
- 2026-08-31 — CNBC-TV18: **Cipla licenses experimental HER2 cancer drug for India, South Africa and five other markets** — Cipla has secured exclusive rights to develop and sell TQB2102 across seven markets, adding a potential treatment for HER2-expressing cancers to its oncology pipeline. — [Source](https://www.cnbctv18.com/business/companies/cipla-licenses-experimental-her2-cancer-drug-for-india-south-africa-and-five-other-markets-19980585.htm)
- 2026-08-26 — BUSINESS: **Stock Alert: Cipla, Varun Beverages, TMPV, United Breweries,Sai Parenterals** — Gaja Alternative Asset Management will list on the stock exchanges today. The IPO was subscribed 31.33 times. The offer received bids for 79.35 crore shares as against 2.53 crore shares on offer. The issue opened for bidding on 19 August 2026 and it closed on 21 August 2026. — [Source](https://www.business-standard.com/markets/capital-market-news/stock-alert-cipla-varun-beverages-tmpv-united-breweries-sai-parenterals-126082600142_1.html)
- 2026-08-26 — BUSINESSTODAY: **Top stocks in news: Groww, Welspun Corp, Gaja Capital, TMPV, Cipla, NBCC, HindCopper, UCO Bank, UPL** — Stocks in news, Stocks in buzz, Stocks to buy, Stocks to watch, Groww, Welspun Corp, Gaja Capital, Tata Motors PV, Cipla, NBCC, Hindustan Copper, UCO Bank, Sai Parenterals, Honasa Consumer, Gaja Alternative Asset Management, Billionbrains Garage Ventures, Varun Beverages, United Breweries, Advait Energy Transitions, ARSS Infrastructure Projects — [Source](https://www.businesstoday.in/markets/stocks/story/top-stocks-in-news-groww-welspun-corp-gaja-capital-tmpv-cipla-nbcc-hindcopper-uco-bank-upl-551349-2026-08-26)
- 2026-08-26 — Economic Times: **Stocks in news: Groww, Tata Motors PV, Cipla, Varun Beverages and Axis Bank** — The Indian equity market experienced a positive turnaround on Tuesday, August 25, highlighted by the Nifty 50 making a robust recovery. Anticipation builds for Wednesday as Groww gears up for a significant block deal, while Cipla faces new USFDA inspectional observations. In other news, Tata Motors Passenger Vehicles is set to enhance its electric vehicle offerings through a collaboration with Tata Communications for 5G technology. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/stocks-in-news-groww-tata-motors-pv-cipla-varun-beverages-and-axis-bank/articleshow/133521013.cms)

## Business profile

**Strategic vision:** Develops, manufactures, and commercializes pharmaceutical products globally.

### Business segments
- **Generic and Branded Formulations:** Manufactures tablets, capsules, injectables, and liquid medicines covering cardiovascular, chronic kidney disease, neuropsychiatry, and anti-infective segments.
- **Respiratory & Inhalation Care:** Develops and produces aerosols, sprays, dry powder inhalers (Revolizer), and metered-dose inhalers (Synchrobreath) for asthma and COPD therapies.
- **Active Pharmaceutical Ingredients (APIs):** Synthesizes bulk chemical actives, custom synthesis compounds, and specialty pharmaceutical intermediates for internal formulation and export.

### Competitive strengths
- Vertically integrated business model
- Focus on complex drug development and device engineering
- In-house manufacturing of critical APIs
- Co-development of drug formulations and proprietary delivery hardware
- Integrated patient care ecosystem

## Related stocks

- [Apollo Hospitals Enterprise Limited (Healthcare)](https://faxioms.com/stocks/apollohosp) — +1.29%
- [Dr. Reddy's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/drreddy) — +0.86%
- [Max Healthcare Institute Limited (Healthcare)](https://faxioms.com/stocks/maxhealth) — -0.57%
- [Sun Pharmaceutical Industries Limited (Healthcare)](https://faxioms.com/stocks/sunpharma) — +0.61%
- [Abbott India Limited (Healthcare)](https://faxioms.com/stocks/abbotindia) — -0.41%

## Freshness and sources

- Data as of: 2026-10-13
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/cipla
Markdown representation: https://faxioms.com/stocks/cipla?render=md